Phase I clinical data on Anti-Notch2/3 were featured in an oral plenary session and additional clinical biomarker data were presented in a poster session.
http://eon.businesswire.com/news/eon/20121109005259/en/OncoMed-Pharmaceuticals-Announces-Presentations-Anti-Notch23-Demcizumab-Clinical
http://eon.businesswire.com/news/eon/20121109005259/en/OncoMed-Pharmaceuticals-Announces-Presentations-Anti-Notch23-Demcizumab-Clinical
No comments:
Post a Comment